Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Top Page
Crispr Therapeutics AG
(NASDAQ:CRSP)
Select Model
Select Model
Rating:47Neutral
Price Target:
$44.00
▼(-14.10% Downside)
Action:ReiteratedDate:03/17/26
The score is held down primarily by weak and inconsistent operating performance (revenue collapse, sustained losses, and cash burn) and bearish technicals (below key moving averages with negative momentum). A solid, low-leverage balance sheet and recent capital raising improve liquidity, but they do not fully offset the current lack of financial consistency and negative momentum; valuation support is also limited due to ongoing losses and no dividend.
Positive Factors
Balance sheet strength
CRISPR has low reported leverage and sizable equity versus debt, providing structural financial flexibility. A stronger balance sheet supports multi-year R&D spend and runway extension without immediate reliance on dilutive equity, aiding sustained clinical advancement.
Negative Factors
Revenue volatility
Revenue is highly episodic and dependent on irregular collaboration/milestone receipts. A ~90% drop in 2025 highlights structural unpredictability in top-line funding, making multi-year planning and reinvestment uncertain without recurring product revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
CRISPR has low reported leverage and sizable equity versus debt, providing structural financial flexibility. A stronger balance sheet supports multi-year R&D spend and runway extension without immediate reliance on dilutive equity, aiding sustained clinical advancement.
Read all positive factors
Crispr Therapeutics AG (CRSP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.92B
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue Growth-81.10%
EPS Growth-99.21%
CountryUS
Employees393
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.37
Shares Outstanding95,985,310
10 Day Avg. Volume1,298,241
30 Day Avg. Volume1,961,443
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.45
Price to Sales (P/S)1343.50
P/FCF Ratio-13.63
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue1.41K
Enterprise Value/Gross Profit-21.76
Enterprise Value/Ebitda-9.48
Forecast
1Y Price Target
$71.29Price Target Upside39.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-4.86
Revenue Forecast (FY)$46.14M
Crispr Therapeutics AG Business Overview & Revenue Model
Company Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. I...
How the Company Makes Money
Crispr Therapeutics makes money primarily through (1) collaboration and partnership revenue and (2) any product-related revenue if/when its therapies are commercialized. Collaboration revenue has historically been a key source, including payments ...
Crispr Therapeutics AG Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Data provided by:
The Fly
The FlyCrispr Therapeutics AG Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.51M | 35.00M | 370.00M | 436.00K | 913.08M |
| Gross Profit | -229.45M | -75.25M | 239.75M | -109.81M | 811.90M |
| EBITDA | -548.84M | -447.31M | -202.70M | -648.99M | 391.48M |
| Net Income | -581.60M | -366.25M | -153.61M | -650.17M | 377.66M |
Balance Sheet | |||||
| Total Assets | 2.27B | 2.24B | 2.23B | 2.24B | 2.75B |
| Cash, Cash Equivalents and Short-Term Investments | 1.98B | 1.90B | 1.69B | 1.82B | 2.38B |
| Total Debt | 394.91M | 223.69M | 238.63M | 244.02M | 225.03M |
| Total Liabilities | 343.43M | 309.95M | 346.77M | 367.58M | 352.42M |
| Stockholders Equity | 1.92B | 1.93B | 1.88B | 1.88B | 2.40B |
Cash Flow | |||||
| Free Cash Flow | -345.93M | -144.68M | -269.85M | -532.93M | 457.27M |
| Operating Cash Flow | -345.01M | -142.77M | -260.38M | -495.74M | 538.97M |
| Investing Cash Flow | -31.80M | -280.48M | 374.65M | -258.65M | -1.04B |
| Financing Cash Flow | 426.03M | 331.98M | 62.66M | 38.59M | 250.94M |
Crispr Therapeutics AG Technical Analysis
Neutral
51.22
Price Trends
51.43
Negative
53.17
Negative
56.33
Negative
Market Momentum
-0.39
Negative
53.41
Neutral
87.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Neutral. The current price of 51.22 is above the 20-day moving average (MA) of 48.28, below the 50-day MA of 51.43, and below the 200-day MA of 56.33, indicating a neutral trend. The MACD of -0.39 indicates Negative momentum. The RSI at 53.41 is Neutral, neither overbought nor oversold. The STOCH value of 87.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRSP.
Crispr Therapeutics AG Risk Analysis
Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Crispr Therapeutics AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $6.94B | -21.09 | -29.08% | ― | -50.05% | -54.47% | |
56 Neutral | $5.21B | 141.40 | 8.20% | ― | 42.11% | ― | |
56 Neutral | $3.36B | -32.35 | -29.22% | ― | 74.91% | 31.54% | |
54 Neutral | $2.79B | -34.27 | -7.31% | ― | -84.07% | -157.71% | |
53 Neutral | $1.59B | -2.54 | -56.63% | ― | 33.52% | 21.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $4.92B | ― | -31.53% | ― | -81.10% | -99.21% |
* Healthcare Sector Average
CRSP
Crispr Therapeutics AG
51.22
12.41
31.98%
NTLA
Intellia Therapeutics
13.49
5.99
79.87%
APLS
Apellis Pharmaceuticals
40.79
21.46
111.02%
BEAM
Beam Therapeutics
27.43
10.43
61.35%
LEGN
Legend Biotech
18.16
-13.95
-43.44%
KYMR
Kymera Therapeutics
85.05
59.62
234.45%
Crispr Therapeutics AG Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Crispr Therapeutics Completes $600 Million Convertible Notes Offering
Positive
Mar 16, 2026
On March 16, 2026, CRISPR Therapeutics AG completed a $600 million private offering of Convertible Senior Notes due 2031, including the full exercise of a $50 million option, with an effective coupon of 1.125% that was increased to 1.7308% to offs...
Business Operations and StrategyPrivate Placements and Financing
Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million
Positive
Mar 11, 2026
On March 10, 2026, CRISPR Therapeutics AG announced plans to privately offer $350 million of convertible senior notes due 2031 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $52....
Business Operations and StrategyProduct-Related Announcements
CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies
Positive
Jan 12, 2026
On January 12, 2026, CRISPR Therapeutics issued an update on its pipeline, underscoring progress across in vivo gene editing, cell therapy and regenerative medicine programs. In 2025, the company reported positive Phase 1 data for CTX310, showing ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.